Syngene International has made the audio recording of its Q1 FY27 earnings call publicly available on its website. The call was conducted on July 30, 2026, and the recording was uploaded on the same day, providing investors and analysts access to management’s commentary on the quarter’s performance.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) regarding the availability of the recording.

Disclosure Details

The intimation was issued by Chethan Yogesh, Company Secretary & Compliance Officer, on July 30, 2026. The audio file is hosted directly on the Syngene International website.

Regulatory Compliance

Under the SEBI Listing Regulations, listed entities are required to make earnings calls accessible to shareholders and stakeholders. By uploading the recording promptly after the event, Syngene ensures transparency and equal access to information for all market participants. The link to the audio file is provided in the exchange filing for record-keeping purposes.

Syngene International reported a consolidated net loss of ₹90 million for the quarter ended June 30, 2026, reversing a profit of ₹867 million in the same period last year. The decline was primarily driven by a foreign exchange fluctuation loss of ₹501 million and exceptional termination benefits of ₹135 million. Consolidated revenue from operations contracted 16% to ₹7,360 million, while standalone revenue fell 17% to ₹6,630 million. Management attributes the operational slowdown to weak biologics demand and currency headwinds.

The Board of Directors approved the unaudited financial results on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial statements were prepared under Indian Accounting Standards (Ind AS) and subjected to a limited review by statutory auditor B S R & Co. LLP. The audit committee reviewed the statements on July 28, 2026. Additionally, the Board recommended a final dividend of ₹1.25 per equity share, subject to shareholder approval at the Annual General Meeting.

Financial Performance Overview

Consolidated revenue from operations declined to ₹7,360 million from ₹8,745 million in Q1FY26. Total income decreased to ₹7,613 million from ₹8,922 million. Operating EBITDA margin compressed sharply to 12.34% from 23.60% in the prior year period. The following table details the key financial metrics:

Standalone revenue fell 17% to ₹6,630 million. Standalone net loss widened to ₹21 million from a profit of ₹740 million in Q1FY26. Total expenses decreased to ₹7,670 million from ₹7,909 million, driven by a 20% drop in material costs to ₹1,734 million and a 4% reduction in staff costs to ₹2,814 million. However, these savings were insufficient to offset the revenue decline and currency headwinds.

Key Loss Drivers and Exceptional Items

The primary drag on profitability was a foreign exchange fluctuation loss of ₹501 million, compared to a loss of just ₹48 million in Q1FY26. Chief Financial Officer Deepak Jain attributed the performance impact to the "lack of offtake from a major biologics client" alongside the forex hedge loss. Additionally, the company recognized ₹135 million as an exceptional item related to termination benefits extended to employees in accordance with approved policy. This follows earlier adjustments for gratuity obligations linked to the new Labour Codes notified by the Government of India in November 2025.

Other income increased 43% to ₹253 million from ₹177 million in the previous year's quarter. The company capitalized ₹293 million under capital work in progress during the quarter, relating to pre-operating costs for its biologics manufacturing facility acquired from Emergent Manufacturing Operations Baltimore, LLC. This facility is expected to increase single-use bioreactor capacity to 50,000L.

Leadership Changes and Strategic Outlook

Kiran Mazumdar-Shaw accepted the role of Executive Chairperson, emphasizing a focus on CDMO and AI-led advanced services. Siddharth Mittal, appointed as Managing Director and CEO, stated his immediate priorities are sharpening commercial execution and building a cost-competitive organization. The Board also appointed Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors, while Dr. Kush Parmar stepped down.

Syngene signed a Memorandum of Understanding with BRIC-Translational Health Science and Technology Institute (THSTI) for early and late-phase clinical development. The company also advanced its Syn.AI platform, developing gigascale virtual screening capabilities. Management expects business momentum to improve in the second half of FY27, targeting single-digit revenue degrowth and mid-20s EBITDA margins for the full year.

What the Numbers Show

The divergence between operational cost discipline and bottom-line erosion highlights Syngene's acute sensitivity to currency volatility and client concentration. While material and staff costs declined by 20% and 4% respectively, the ₹501 million forex loss alone exceeded the entire PAT from Q1FY26. The compression of EBITDA margins from 23.60% to 12.34% underscores the challenge of maintaining profitability amid headwinds in the biologics segment. The strategic pivot toward AI and CDMO services aims to diversify revenue streams, but near-term results remain constrained by the delayed offtake from key clients.